Press Releases

Dr. Navid Malik and Mr. Jerry Jasinowski Bring Extensive Experience to the Board Bethesda, Maryland, April 17, 2012 – Northwest Biotherapeutics (OTC Bulletin Board: NWBO) (NW Bio), a biotech company developing DCVax® personalized immune therapies for cancer, is pleased to announce the addition of Dr. Navid Malik and Mr. Jerry Jasinowski to the Company’s Board of Directors. These new members bring to the NW Bio Board longstanding, deep... Read More

Programs Include Both Clinical Trial and Compassionate Use Bethesda, Maryland, April 12, 2012 – Northwest Biotherapeutics (OTC Bulletin Board: NWBO) (NW Bio) announced today that it is partnering with King’s Health Partners to both manufacture and deliver a new treatment for patients with brain cancer as part of its ongoing 240-patient clinical trial for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. Specialists... Read More

COO Dr. Anthony Maida To Discuss “Industry Innovators Blazing The Trail Towards Successful and Sustained Commercialization” BETHESDA, MD, February 29, 2012 — Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) today announced that its COO, Anthony Maida III, Ph.D., MA, MBA, will be presenting at the Cancer Immunotherapy Conference as the lead afternoon speaker at 1:45 pm on Wednesday, February 29, 2012, in Boston,... Read More

Projections Met or Exceeded For Fourth Consecutive Quarter BETHESDA, MD, February 23, 2012 — Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) today announced that it now has 30 clinical trial sites open and recruiting across the United States in its ongoing Phase 2 clinical trial of DCVax®-L immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. The Company reached this milestone ahead of schedule, as... Read More

Initial Focus On Current 240-Patient GBM Clinical Trial BETHESDA, MD, February 21, 2012 — Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) today announced that it has entered into an agreement with the American Red Cross to provide blood collection services through which immune cells are obtained to make DCVax®-L treatments for brain cancer patients. The services are focused initially on the Company’s ongoing Phase II clinical trial... Read More